ArticleScientific reports2025
Contrast-enhanced mammography for tumor size assessment and detection of multifocal and multicentric disease in breast cancer subtypes.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The role of Contrast-Enhanced Mammography (CEM) in preoperative staging of breast cancer with different histological types and molecular subtypes is investigated by assessing the size of the primary tumor and distinguishing multifocal and/or multicentric breast cancer (MMBC). Data were continuously collected from patients who underwent CEM imaging due to suspected breast lesions from July 2019 to July 2024. The correlation between CEM measurements and histopathological size measurements was analyzed by using Pearson correlation coefficients. Bland-Altman plots were constructed to compare the agreement between tumor size measured by CEM and tissue pathology size measurements from surgical specimens. The presence of multifocal and/or multicentric disease is also evaluated. The correlation between CEM-measured maximum tumor size and pathological measurements is poorer for non-special type/invasive ductal carcinoma compared to other histological types, with HER2 and triple-negative molecular subtypes showing better correlation than luminal A and luminal B subtypes. The frequency of MMBC identified solely by CEM did not show statistically significant differences across histological types or molecular subtypes. This retrospective study indicates that histological type and molecular subtype may influence the assessment of tumor size in breast cancer using CEM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.